[HTML][HTML] MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

S Jarius, F Paul, O Aktas, N Asgari, RC Dale… - Journal of …, 2018 - Springer
S Jarius, F Paul, O Aktas, N Asgari, RC Dale, J De Seze, D Franciotta, K Fujihara, A Jacob
Journal of neuroinflammation, 2018Springer
Over the past few years, new-generation cell-based assays have demonstrated a robust
association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein
(MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well
as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now
consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right,
immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 …
Abstract
Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation.
Springer